• Cerespir Inc., of New York, disclosed positive interim clinical results from the Phase II trial by Chiesi Farmaceutici SpA, of Parma, Italy, testing CHF 5074, a first-in-class small-molecule microglia modulator, in patients with mild cognitive impairment (MCI).